With two RNA manipulation platforms united under one roof, Dutch biotech Vico will deploy its new series A round for clinical development of a program founder and Chairman Luc Dochez knows well from his time...

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target. Investors immediately soured on Wednesday’s...

Hemophilia A is expected to be the next market where gene therapies will create competition, but long-term durability remains a key unknown. While the BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) therapy valoctocogene roxaparvovec, or “valrox,” maintains Factor...

Fresh off Sanofi’s sell-off, Regeneron announced an expanded collaboration with gene editing company Intellia that gives the big biotech access to the coveted CRISPR gene editing technology for additional targets and indications, including hemophilia. The...

BioMarin’s gene therapy deal with DiNAQOR represents the first step in the company's plans to expand its gene therapy pipeline, while entering what’s becoming a hot cardiovascular indication: cardiomyopathy. The companies partnered to develop gene...

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...

BioMarin's hemophilia gene therapy gets Priority Review BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) could become the first company to have a hemophilia gene therapy approved in the U.S. FDA accepted and granted Priority Review to a BLA...

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...